Ricks Renews PhRMA Call For Comprehensive Japan Policy Dialog
'Transparency And Predictability' Needed
Executive Summary
US research-based group again calls for a comprehensive dialog with all healthcare system stakeholders in Japan to address what it sees as "harmful" policies that have reduced the country's support for innovation and attractiveness as a market for drug development amid the rapid rise of some regional neighbors.
You may also be interested in...
Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite
The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.
New Options For Japan As More COVID-19 Vaccines Finally Approved
Japan has granted emergency approvals to two more vaccines for COVID-19, both from multinational developers, as it finally expands a so far very limited armory against the pandemic.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.